clinical trial retatrutide VisualAbstract: reduces body weight by 17.5% in patients with obesity Today, we shared new data

Combination Therapy: For patients with established cardiovascular disease AND obesity, combination therapy with both medications may provide optimal benefitsup to 1.8% additional A1C reduction and 25% weight loss

Dosing regimens for both products involve gradual titration to optimize therapeutic outcomes

Do not use if you or your family have a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)

One is the GLP-1 receptor

However, as of 2023, lixisenatide is no longer available as a standalone agent in the USA

If you're on a GLP-1, here's how that approach helps you preserve muscle and stay strong through the process: We program full-body strength 2 to 3 times per week